Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Aytu Biopharma (AYTU) Accumulated Depreciation & Amortization (2016 - 2026)

Aytu Biopharma has reported Accumulated Depreciation & Amortization over the past 14 years, most recently at $768000.0 for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 17.97% to $768000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $768000.0 through Dec 2025, up 17.97% year-over-year, with the annual reading at $714000.0 for FY2025, 66.4% down from the prior year.
  • Accumulated Depreciation & Amortization was $768000.0 for Q4 2025 at Aytu Biopharma, up from $735000.0 in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $9.4 million in Q2 2022 and troughed at -$3.3 million in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $1.9 million (2022), against an average of $2.0 million.
  • The largest YoY upside for Accumulated Depreciation & Amortization was 912.0% in 2021 against a maximum downside of 6560.78% in 2021.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at -$3.3 million in 2021, then soared by 192.99% to $3.1 million in 2022, then increased by 0.46% to $3.1 million in 2023, then plummeted by 78.85% to $651000.0 in 2024, then grew by 17.97% to $768000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Accumulated Depreciation & Amortization are $768000.0 (Q4 2025), $735000.0 (Q3 2025), and $714000.0 (Q2 2025).